logo
From painkillers to antibiotics: Five medicines that could harm your hearing

From painkillers to antibiotics: Five medicines that could harm your hearing

Malay Mail22-07-2025
LONDON, July 22 — When we think about the side effects of medicines, we might think of nausea, fatigue or dizziness. But there's another, lesser-known risk that can have lasting — and sometimes permanent — consequences: hearing loss.
A wide range of prescription and over-the-counter drugs are known to be ototoxic, meaning they can damage the inner ear and affect hearing or balance.
Ototoxicity refers to drug or chemical-related damage to the cochlea, which affects hearing, and the vestibular system, which controls balance.
Symptoms can include tinnitus (ringing in the ears), hearing loss (often starting with high-frequency sounds), dizziness or balance problems or a sensation of fullness in the ears.
These effects can be temporary or permanent, depending on the drug involved, the dose and duration and a person's susceptibility.
The inner ear is highly sensitive, and most experts believe ototoxic drugs cause damage by harming the tiny hair cells in the cochlea or disrupting the fluid balance in the inner ear. Once these hair cells are damaged, they don't regenerate — making hearing loss irreversible in many cases.
Around 200 medicines are known to have ototoxic effects. Here are some of the most commonly used drugs to watch out for:
1. Antibiotics
Aminoglycoside antibiotics like gentamicin, tobramycin and streptomycin are typically prescribed for serious infections such as sepsis, meningitis, or tuberculosis — conditions where prompt, aggressive treatment can be lifesaving. In these cases, the benefits often outweigh the potential risk of hearing loss.
These drugs, usually given intravenously, are among the most well-documented ototoxic medications. They can cause irreversible hearing loss, particularly when used in high doses or over extended periods. Some people may also be genetically more vulnerable to these effects.
These drugs linger in the inner ear for weeks or even months, meaning damage can continue after treatment has ended.
Other antibiotics to be aware of include macrolides (such as erythromycin and azithromycin) and vancomycin, which have also been linked to hearing problems, particularly in older adults or people with kidney issues.
2. Heart medicines
Loop diuretics like furosemide and bumetanide are commonly used to manage heart failure or high blood pressure. When given in high doses or intravenously, they can cause temporary hearing loss by disrupting the fluid and electrolyte balance in the inner ear. Around 3 per cent of users may experience ototoxicity.
Some blood pressure medications have also been linked to tinnitus.
These include ACE inhibitors — drugs like ramipril that help relax blood vessels by blocking a hormone called angiotensin, making it easier for the heart to pump blood — and calcium-channel blockers like amlodipine, which reduce blood pressure by preventing calcium from entering the cells of the heart and blood vessel walls. While these associations have been observed, more research is needed to fully understand the extent of their effect on hearing.
3. Chemotherapy
Certain chemotherapy drugs, especially those containing platinum — like cisplatin and carboplatin — are known to be highly ototoxic. Cisplatin, often used to treat testicular, ovarian, breast, head and neck cancers, carries a significant risk of permanent hearing loss. That risk increases when radiation is also directed near the head or neck.
Up to 60 per cent of patients treated with cisplatin experience some degree of hearing loss. Researchers are exploring ways to reduce risk by adjusting dosage or frequency without compromising the drug's effectiveness.
4. Painkillers
High doses of common pain relievers, including aspirin, NSAIDs — non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen, commonly used to relieve pain, inflammation and fever — and even paracetamol, have been linked to tinnitus and hearing loss.
A large study found that women under 60 who regularly took moderate-dose aspirin (325 mg or more, six to seven times per week) had a 16 per cent higher risk of developing tinnitus.
This link was not seen with low-dose aspirin (100 mg or less). Frequent use of NSAIDs as well as paracetamol was also associated with a nearly 20 per cent increased risk of tinnitus, particularly in women who used these medications often.
Another study linked long-term use of these painkillers to a higher risk of hearing loss, especially in men under 60. In most cases, tinnitus and hearing changes resolve once the medication is stopped — but these side effects typically occur after prolonged, high-dose use.
5. Antimalarial drugs
Drugs like chloroquine and quinine — used to treat malaria and leg cramps — can cause reversible hearing loss and tinnitus. One study found that 25-33 per cent of people with hearing loss had previously taken one of these drugs.
Hydroxychloroquine, used to treat lupus and rheumatoid arthritis, has a similar chemical structure and poses a similar risk. While some people recover after stopping the drug, others may experience permanent damage, particularly after long-term or high-dose use.
People with pre-existing hearing loss, kidney disease, or genetic susceptibility face higher risks — as do those taking multiple ototoxic drugs at once. Children and older adults may also be more vulnerable.
If you're prescribed one of these medications for a serious condition like cancer, sepsis or tuberculosis, the benefits usually outweigh the risks.
But it's still wise to be informed. Ask your doctor or pharmacist if your medicine carries a risk to hearing or balance. If you experience ringing in your ears, dizziness, or muffled hearing, report it promptly. — Reuters
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030
AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

Malay Mail

time2 days ago

  • Malay Mail

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

LONDON, July 29 — AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the US, where it has invested US$50 billion (RM212 billion) to expand amid tariff threats from Washington. The performance is a boost for the UK's largest-listed company by market value as the wider sector braces for US tariffs on pharmaceutical imports and navigates pressure after President Donald Trump's order pushing for drugmakers to cut US prices to what other countries pay. AstraZeneca shares rose as much as 2.2 per cent by 0813 GMT. The drugmaker in April forecast only a limited impact from potential US tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-US trade deal over the weekend will result in a 15 per cent tariff on pharmaceuticals from the region. The US accounted for more than 40 per cent of AstraZeneca's revenue in 2024. The company had prioritised the market — the world's largest, worth US$635 billion — even before Trump's return to office. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its US expansion to reach US$80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3 per cent. 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' CEO Pascal Soriot said. Cancer drugs outperform Sales of oncology drugs, constituting nearly half of AstraZeneca's revenue, were up 18 per cent at US$6.31 billion at constant currency rates in the quarter. Jefferies analysts said sales of drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Total revenue for the three months ended June grew 11 per cent to US$14.46 billion, with double-digit growth in the US despite headwinds from changes in US Medicare price negotiations. Core earnings stood at US$2.17 per share. That compares with analysts' expectations of US$2.16, and US$14.15 billion in sales, according to a company-provided consensus. 'Operationally, this is the type of quarter we want to see,' Barclays analysts said. AstraZeneca is also hoping to move on from scandals in its second-biggest market, China, where it this year faced minor fines related to cancer drugs. It is also fighting patent challenges from an individual against Tagrisso. The company also delayed late-stage Avanzar trial data for a key lung cancer treatment to the first half of 2026. — Reuters

Global liver cancer cases set to nearly double by 2050 without action, study warns
Global liver cancer cases set to nearly double by 2050 without action, study warns

Malay Mail

time2 days ago

  • Malay Mail

Global liver cancer cases set to nearly double by 2050 without action, study warns

PARIS, July 29 — The number of people with liver cancer will nearly double worldwide by 2050 unless more is done to address preventable causes such as obesity, alcohol consumption and hepatitis, a study warned today. New cases of liver cancer—the sixth most common form of the disease—will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal. It is also the third deadliest of all cancers, with the study predicting it would take 1.37 million lives by the middle of the century. However three out of five cases of liver cancer could be prevented, the international team of experts said. The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called MASLD, which was previously known as non-alcoholic fatty liver disease. The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022. Cancer due to obesity-linked fat in livers will rise to 11 percent, also up more than two percentage points, the researchers calculated. The large-scale study, which reviewed the available evidence on the subject, underscored 'the urgent need for global action' on liver cancer, the authors said. The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people with obesity or diabetes about fatty-liver disease in the United States, Europe and Asia.— AFP

7,000 steps ‘enough to significantly boost health'
7,000 steps ‘enough to significantly boost health'

Free Malaysia Today

time2 days ago

  • Free Malaysia Today

7,000 steps ‘enough to significantly boost health'

Walking 7,000 steps a day is linked to 38% reduction in risk of dementia, depression (22%) and diabetes (14%), as well as lower rates of cancer and falls. (Envato Elements pic) PARIS : People who walk 7,000 steps a day have a dramatically lower risk of a broad range of serious health problems, according to the largest review of evidence yet. The most widely promoted target for people tracking their number of steps is 10,000 – but that figure reportedly originally came from a 1960s marketing campaign for a Japanese paedometer. To find a more scientific target, an international team of researchers sifted through 57 previous studies that covered 160,000 people. The results, published in Lancet Public Health, found that walking 7,000 steps a day nearly halved people's risk of early death from all causes, compared to 2,000 steps. The study also looked into health problems not previously covered by research into step counts. Walking 7,000 steps a day was linked to dementia risk falling by 38%, depression by 22%, and diabetes by 14%. It was also associated with lower rates of cancer and falls, though the researchers warned this was based on less evidence. 'You don't need to hit 10,000 steps a day to get major health benefits,' Paddy Dempsey, a study co-author and medical researcher at Cambridge University, told AFP. 'The biggest gains happen before 7,000 steps, and then benefits tend to level off.' While people's speeds vary widely, 7,000 steps adds up to roughly an hour of walking throughout the day. Dempsey emphasised that people already managing 10,000 or more steps should keep it up. But he had a message for people who might find 7,000 steps daunting: 'Don't be discouraged.' 'If you're only getting 2,000-3,000 steps a day, aim to add an extra 1,000 steps. That's just 10-15 minutes of light walking spread across the day,' he advised. Andrew Scott, a researcher at the University of Portsmouth not involved in the study, said 'it demonstrates that overall, more is always better'. 'People should not focus too much on the numbers, particularly on days where activity is limited,' he added. The World Health Organization recommends at least 150 minutes of moderate to intense physical activity a week. Nearly a third of people worldwide do not reach this target, according to WHO.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store